Literature DB >> 1516656

Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes.

G Hilf1, K H Jakobs.   

Abstract

Agonist activation of muscarinic acetylcholine (mACh) receptors in porcine atrial membranes stimulates binding of the GTP analog, guanosine 5'-O-[gamma-thio]triphosphate (GTP[S]), to membrane G proteins. In contrast, atropine as well as several other mACh receptor antagonists reduced the binding of GTP[S] below basal values, both in the absence and presence of the agonist carbachol, by a similar maximal extent (about 25%). Evidence is presented that this inhibitory action of atropine was not due to an antagonism of endogenous acetylcholine. Similar to agonist-induced stimulation, antagonist-induced inhibition of GTP[S] binding required the presence of GDP and Mg2+. On the other hand, addition of salts, e.g. NaCl, amplified agonist but reduced antagonist effects on GTP[S] binding. The data presented suggest that agonist-unliganded mACh receptors interact with and activate G proteins in native cardiac membranes and that antagonist binding induces a conformational change of the receptor, which then either does not interact with G proteins or which prevents GDP release from and subsequent GTP[S] binding to G proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516656     DOI: 10.1016/0922-4106(92)90026-r

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

Review 1.  Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.

Authors:  R A de Ligt; A P Kourounakis; A P IJzerman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 2.  Review: amino acid domains involved in constitutive activation of G-protein-coupled receptors.

Authors:  P J Pauwels; T Wurch
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

3.  Activation of muscarinic acetylcholine receptors via their allosteric binding sites.

Authors:  J Jakubík; L Bacáková; V Lisá; E E el-Fakahany; S Tucek
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

Review 4.  cAMP guided his way: a life for G protein-mediated signal transduction and molecular pharmacology-tribute to Karl H. Jakobs.

Authors:  Klaus Aktories; Peter Gierschik; Dagmar Meyer Zu Heringdorf; Martina Schmidt; Günter Schultz; Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-17       Impact factor: 3.000

5.  Electroacupuncture brain protection during ischemic stroke: A role for the parasympathetic nervous system.

Authors:  Laiting Chi; Kairong Du; Dongdong Liu; Yulong Bo; Wenzhi Li
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-10       Impact factor: 6.200

6.  Inverse agonist activity of pirenzepine at M2 muscarinic acetylcholine receptors.

Authors:  L Daeffler; F Schmidlin; J P Gies; Y Landry
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

7.  Inhibition of GTPase activity of Gi proteins and decreased agonist affinity at M2 muscarinic acetylcholine receptors by spermine and methoctramine.

Authors:  L Daeffler; A Chahdi; J P Gies; Y Landry
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

8.  Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium.

Authors:  D R Varma; H Shen; X F Deng; K G Peri; S Chemtob; S Mulay
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

9.  Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus.

Authors:  D E Selley; C C Cao; Q Liu; S R Childers
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

10.  Pharmacological characterization of acetylcholine-stimulated [35S]-GTP gamma S binding mediated by human muscarinic m1-m4 receptors: antagonist studies.

Authors:  S Lazareno; N J Birdsall
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.